Diabetes mellitus
The reference is the ADA Standards of Care in Diabetes, updated every January in a supplement to Diabetes Care. The 2026 edition is summarised here.
What's new in recent editions
- Organ protection first: SGLT2i and GLP-1 RA choices are driven by ASCVD, heart failure, CKD and MASLD, irrespective of A1C.
- GLP-1-based therapy before insulin for most people with type 2 diabetes.
- Tirzepatide (dual GIP/GLP-1 RA) for obesity with HFpEF, and for weight.
- SGLT2i can continue below eGFR 20 until dialysis; GLP-1 RA can be used on dialysis.
- LDL goal <55 mg/dL (1.4 mmol/L) with established ASCVD.
- Finerenone with an SGLT2i for diabetic kidney disease with albuminuria.
Clinical pearls
- Euglycaemic DKA with SGLT2 inhibitors: ketoacidosis with near-normal glucose.
- A1C is unreliable in pregnancy, haemoglobin variants, G6PD deficiency, HIV and anything that changes red-cell turnover: use glucose.
- Over-basalisation: a big bedtime-to-morning or postprandial-to-preprandial drop, hypoglycaemia or high variability means too much basal insulin.